Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

Diabetic Medicine

Volumn 29, Issue 5, 2012, Pages 690-692

  Thong, K Y ^a   Ryder, R E J ^a   Cull, M L ^a   Walton, C ^b  

^a CITY HOSPITAL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; SULFONYLUREA;

BODY MASS; CLINICAL PRACTICE; DIABETIC PATIENT; DISEASE ASSOCIATION; DRIVER LICENCE; DRUG INDICATION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK ASSESSMENT; TREATMENT RESPONSE; WEIGHT REDUCTION;

AUTOMOBILE DRIVING; BLOOD GLUCOSE; DEVICE APPROVAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GREAT BRITAIN; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LICENSURE; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 84859820777     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03475.x     Document Type: Letter

References (7)

1. Drivers Medical Group DVLA. At-A-Glance Guide to the Current Medical Standards of Fitness to Drive. Swansea: Driver and Vehicle Licensing Agency, 2010.
2. Diabetes UK. Website Information on Living with Diabetes-Driving. Available at Last accessed 27 April 2011.
3. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007; 298: 194-206.
4. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral anti-diabetic drug therapy in type2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11: 1163-1172.
5. National Institute for Health and Clinical Excellence. Type2 Diabetes: Newer Agents for Blood Glucose Control in Type2 Diabetes. NICE short clinical guideline87. 2009. Available at Last accessed 27 April 2011.
6. National Institute for Health and Clinical Excellence. Liraglutide for the Treatment of Type2 Diabetes. NICE technology appraisal guidance203. 2010. Available at last accessed 27 April 2011.
7. Thong KY, Jose B, Blann AD, Cull ML, Mills AP, Sathyapalan T et al. Response at 3months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract 2011; 93: e87-91.